U.S. markets open in 7 hours 27 minutes
  • S&P Futures

    3,793.00
    -28.25 (-0.74%)
     
  • Dow Futures

    30,817.00
    -182.00 (-0.59%)
     
  • Nasdaq Futures

    11,591.25
    -99.75 (-0.85%)
     
  • Russell 2000 Futures

    1,708.60
    -12.80 (-0.74%)
     
  • Crude Oil

    110.02
    +0.24 (+0.22%)
     
  • Gold

    1,816.70
    -0.80 (-0.04%)
     
  • Silver

    20.70
    -0.04 (-0.18%)
     
  • EUR/USD

    1.0460
    +0.0016 (+0.16%)
     
  • 10-Yr Bond

    3.0930
    0.0000 (0.00%)
     
  • Vix

    28.16
    -0.20 (-0.71%)
     
  • GBP/USD

    1.2147
    +0.0025 (+0.20%)
     
  • USD/JPY

    136.3410
    -0.2040 (-0.15%)
     
  • BTC-USD

    20,003.27
    -167.61 (-0.83%)
     
  • CMC Crypto 200

    429.53
    -10.13 (-2.31%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • Nikkei 225

    26,336.11
    -468.49 (-1.75%)
     

AIkido Pharma Inc. Announces Participation in the Benzinga Global Small Cap Conference

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Detroit, Michigan--(Newsfile Corp. - May 6, 2021) -  AIkido Pharma Inc. (NASDAQ:AIKI) will be presenting at the Benzinga Global Small Cap Conference taking place on May 13-14, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space.

Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/global/

About the Benzinga Global Small Cap Conference

The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders. Learn about small cap investing with clearly defined educational modules, take a look at a curated group of small cap investment opportunities, and connect with the global small cap audience in an intimate, virtual setting.

For more information and/or to register for the conference please visit: https://www.benzinga.com/events/small-cap/global/

We look forward to seeing you there.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82705